Buchumschlag

Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma

A standard treatment option for patients with locally advanced thoracic esophageal squamous cell carcinoma (TESCC) is trimodality therapy, often consisting of neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery (1-4). However, transhiatal esophagectomy poses significant risks, includ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Post, Carl M. (VerfasserIn) , Häfner, Matthias (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2017
In: Translational cancer research
Year: 2017, Jahrgang: 6, Pages: S625-S628
ISSN:2219-6803
DOI:10.21037/tcr.2017.05.26
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.21037/tcr.2017.05.26
Verlag, kostenfrei, Volltext: http://tcr.amegroups.com/article/view/13590
Volltext
Verfasserangaben:Carl M. Post, Matthias F. Haefner, Chi Lin, Charles B. Simone II, Vivek Verma

MARC

LEADER 00000caa a2200000 c 4500
001 1578252334
003 DE-627
005 20230426230841.0
007 cr uuu---uuuuu
008 180803s2017 xx |||||o 00| ||eng c
024 7 |a 10.21037/tcr.2017.05.26  |2 doi 
035 |a (DE-627)1578252334 
035 |a (DE-576)508252334 
035 |a (DE-599)BSZ508252334 
035 |a (OCoLC)1341016166 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Post, Carl M.  |e VerfasserIn  |0 (DE-588)1163849960  |0 (DE-627)1028187327  |0 (DE-576)508252237  |4 aut 
245 1 0 |a Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma  |c Carl M. Post, Matthias F. Haefner, Chi Lin, Charles B. Simone II, Vivek Verma 
264 1 |c 2017 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 03.08.2018 
520 |a A standard treatment option for patients with locally advanced thoracic esophageal squamous cell carcinoma (TESCC) is trimodality therapy, often consisting of neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery (1-4). However, transhiatal esophagectomy poses significant risks, including tracheal and pulmonary injury, anastomotic leak, vagus nerve injury, infection, and death. Therefore, two randomized trials have addressed this concern by comparing definitive CCRT (dCCRT) alone versus neoadjuvant CCRT (nCCRT) plus surgery in esophageal cancer (5,6). Both trials found no difference in overall survival (OS), but fewer local recurrences were observed in the nCCRT plus surgery groups. Major limitations of these trials included salvage therapy potentially confounding OS, the usage of induction chemotherapy (which is a widely utilized treatment strategy), patient selection based on induction chemotherapy response (6), and diminished applicability to current practice utilizing more advanced radiation techniques like intensity-modulated radiation therapy (IMRT). Consequently, recent high volume data addressing the therapeutic benefits of dCCRT versus nCCRT followed by surgery are lacking, and such data are needed to help inform the optimal management approach for TESCC. 
700 1 |a Häfner, Matthias  |d 1983-  |e VerfasserIn  |0 (DE-588)101371993X  |0 (DE-627)664930042  |0 (DE-576)347618065  |4 aut 
773 0 8 |i Enthalten in  |t Translational cancer research  |d Shatin : AME Publishing Company, 2012  |g 6(2017), Supplement 3, Seite S625-S628  |h Online-Ressource  |w (DE-627)894990276  |w (DE-600)2901601-0  |w (DE-576)491668899  |x 2219-6803  |7 nnas  |a Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma 
773 1 8 |g volume:6  |g year:2017  |g supplement:Supplement 3  |g pages:S625-S628  |g extent:4  |a Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma 
856 4 0 |u http://dx.doi.org/10.21037/tcr.2017.05.26  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://tcr.amegroups.com/article/view/13590  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180803 
993 |a Article 
994 |a 2017 
998 |g 101371993X  |a Häfner, Matthias  |m 101371993X:Häfner, Matthias  |d 910000  |d 911400  |e 910000PH101371993X  |e 911400PH101371993X  |k 0/910000/  |k 1/910000/911400/  |p 2 
999 |a KXP-PPN1578252334  |e 3020207258 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1578252334","language":["eng"],"note":["Gesehen am 03.08.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma","title_sort":"Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Post, Carl M.","given":"Carl M.","family":"Post"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Häfner, Matthias","given":"Matthias","family":"Häfner"}],"relHost":[{"title":[{"title_sort":"Translational cancer research","title":"Translational cancer research","subtitle":"TCR"}],"part":{"volume":"6","text":"6(2017), Supplement 3, Seite S625-S628","extent":"4","year":"2017","pages":"S625-S628"},"titleAlt":[{"title":"Transl Cancer Res TCR"},{"title":"TCR"}],"pubHistory":["Vol 1, no 1 (June 2012)-"],"language":["eng"],"recId":"894990276","disp":"Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinomaTranslational cancer research","type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["2219-6803"],"zdb":["2901601-0"],"eki":["894990276"]},"origin":[{"publisherPlace":"Shatin","dateIssuedDisp":"[2012]-","publisher":"AME Publishing Company"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"4 S."}],"id":{"doi":["10.21037/tcr.2017.05.26"],"eki":["1578252334"]},"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}],"name":{"displayForm":["Carl M. Post, Matthias F. Haefner, Chi Lin, Charles B. Simone II, Vivek Verma"]}} 
SRT |a POSTCARLMHNEOADJUVAN2017 

Ähnliche Einträge